Phage Therapy: The Forgotten Cure Making a Comeback
Introduction: The Age of Superbugs and a Century-Old Solution
Antibiotics used to transform medicine, but now their efficacies are disappearing. With antibiotic resistance on the rise, we are being forced to look back in time for forgotten answers. An answer for this? Phage therapy - a century-old microbial assassin that may rescue modern medicine.
What are Bacteriophages?
If you didn't read our detailed article on these microbes, have a look at The Viral Side of Life: How Bacteriophages Rule the Microbial World. Phages or bacteriophages, are viruses that attack and eliminate only some specific strains of bacteria. While common antibiotics destroy both the good and the bad bacteria, phages only attack and kill the harmful ones. Therefore, they offer a bright chance to create personalized medicine for superbugs.
Why Was Phage Therapy Abandoned?
Phage therapy first gained traction in the early 20th century, even before antibiotics. But due to:
- Unpredictable results,
- Limited understanding of viruses, and
- The explosive success of penicillin in the 1940s, phage therapy fading from mainstream medicine, except in places like Georgia and Russia, where it quietly continued
- Advances in genome sequencing allow rapid phage identification
- Synthetic biology helps engineer "super phages" with enhanced killing power
- Successful clinical trials and last-resort treatments are showing remarkable recovery stories
- UK Miracle Case: A teenage girl suffering from a nearly untreatable Mycobacterium abscessus infection post-lung transplant was given genetically engineered phages as a last resort. Her condition dramatically improved, marking one of the first life-saving uses of modified phages in humans [Link: https://pubmed.ncbi.nlm.nih.gov/31068712/]
- US Phage Cocktails in Action: A team of researchers is busy using phage cocktails to fight multidrug-resistant strains of Pseudomonas aeruginosa and Klebsiella pneumoniae, which are known to cause severe hospital-acquired infections. Early results from compassionate use cases are showing promising outcomes [Link: https://www.nature.com/articles/s41598-023-36034-2, https://www.nature.com/articles/s41522-024-00603-8]
- Spare beneficial gut bacteria
- Multiply at the infection site
- Co-evolve with bacteria, reducing resistance buildup
- Can be genetically modified to enhance performance
- Regulatory ambiguity
- Complex manufacturing & storage
- Need for personalized phage-bacteria matching
Comments
Post a Comment